Content area

|
|

Akut promyelocytleukæmi

Forfatter(e)
Michael Tøstesen, Lene S.G. Østgård, Eigil Kjeldsen, Jesper Stentoft & Jan M. Nørgaard Hæmatologisk Afdeling, Aarhus Universitetshospital Ugeskr Læger 2018;180:V06170490
Reference: 
Ugeskr Læger 2018;180:V06170490
Blad nummer: 
Sidetal: 
2-5
Acute promyelocytic leukaemia
Acute promyelocytic leukaemia has changed from being a highly fatal to a highly curable disease. Over time, key discoveries have identified the genetic and molecular abnormalities, which cause the disease. First choice of treatment has now changed from all-trans retinoic acid (ATRA) and chemotherapy to a chemo-free combination of arsenic trixoide and ATRA. This new regimen has shown equal responses and overall cure rates compared with the previous standard of care containing conventional chemotherapy, but with much lower toxicity. This will pave the way for better and easier treatment for elderly and frail patients.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Anders Heissel | 18/09
2 kommentarer
af Alice Kunkel | 17/09
7 kommentarer
af Jørn Rosborg | 17/09
1 Kommentar
af Peter Christian Gøtzsche | 17/09
1 Kommentar
af Jens Ole Mathiesen | 16/09
3 kommentarer
af Annette Randløv | 16/09
2 kommentarer
af Jens Ole Mathiesen | 15/09
4 kommentarer
af Jens Ole Mathiesen | 14/09
4 kommentarer
af Steffen Thirstrup | 11/09
4 kommentarer
af Jane Skjøth-Rasmussen | 11/09
8 kommentarer